Clinton Bans HMO Gags On Medicare Patients

3 March 1997

US President Bill Clinton has prohibited health maintenanceorganizations from limiting what doctors tell Medicaid patients about potential treatments. Also, to protect 130 million people enrolled in managed care through the private sector, he urged Congress to pass, without delay, a bipartisan bill banning plans from imposing gag clauses, saying he would sign this promptly.

The American Association of Health Plans says the bill goes beyond open patient/doctor discussions on treatment options and, as it stands, would have adverse consequences; it could keep HMOs from giving doctors the latest research on better ways to practice. HMOs say the only limits on communications are those that stop doctors from speaking badly of plans with which they are associated.

About 5 million Medicare beneficiaries (12% of the total) and 12 million Medic-aid recipients (over a third) are enrolled in HMOs or other managed care plans, says the Wall Street Journal. In December, the administration banned gag clauses in plans treating Medicare patients (Marketletter December 16, 1996).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight